Our approach targets the core pathological processes of Alzheimer's:

​

• Selective Removal of Intracellular Tau Aggregates: Our innovative therapy directly targets the accumulation of intracellular tau aggregates—recognized as a primary cause of neurodegeneration and cognitive decline in Alzheimer's Disease. Unlike conventional treatments primarily aimed at reducing inflammation or managing secondary symptoms, our approach tackles the underlying pathology by facilitating the intracellular disposal of tau proteins. Currently, no other treatment provides this targeted solution.

• Promoting Neuroregeneration: By leveraging native human genes, our therapy actively stimulates multiple regeneration processes within the brain. It supports damaged neurons in their recovery and enhances their capability to re-establish functional synaptic connections. Additionally, our therapy provides robust neuroprotective effects, safeguarding existing neurons from further degeneration. This combined approach of neuron repair and neuroprotection ensures effective reintegration into existing neural networks, ultimately resulting in significant improvements in cognitive and neurological functions for Alzheimer's patients.